Skip to main content

Immunology Market to Exhibit a CAGR of 8.1% by 2026; Growing R&D Investment by Major Players to Aid Development, states Fortune Business Insights™

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, May 28, 2020 (GLOBE NEWSWIRE) — The global immunology market size is predicted to reach USD 143,833.2 million by 2026, exhibiting a CAGR of 8.1% during the forecast period. The growing cases of immunological and autoimmune diseases will aid the growth of the market during the forecast period, states Fortune Business Insights in a report, titled “Immunology Market Size, Share and Industry Analysis By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressant, Polyclonal antibody (pAb), Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, Others), By Distribution Channel, and Regional Forecast 2019-2026” the market size stood at USD 77,365.4 million in 2018. The growing R&D investment by major key players will foster the growth of the market in the forthcoming years.Launch of Novel therapies to Drive MarketThe introduction of novel therapeutics by key players will have a positive impact on the market during the forecast period. for instance, the release of Cosentyx by Novartis AG, a therapy for the treatment of plaque psoriasis in adults. The growing adoption of monoclonal antibody (mAb) in the treatment of immunological diseases will subsequently bolster the healthy growth of the market. The increasing R&D activities for the development of advanced monoclonal antibody will enable speedy expansion of the market during the forecast period. The growing emphasis on targeted therapy will have a positive influence on the market. The innovation and advancement of existing drugs for better treatment outcomes for the patients will promote the growth of the market.The growing awareness regarding immunological diseases in both developing and developed nations will spur opportunities for the market during the forecast period. The increasing cases of immunological disorders will foster healthy growth of the market during the forecast period. In addition, the introduction of innovative drugs by pre-eminent players will bolster the growth of the market in the foreseeable future. For instance, Janssen Global Services, LLC (Johnson & Johnson) announced the release of TREMFYA (guselkumab) for the treatment of moderate to severe plaque psoriasisAn Overview of the Impact of COVID-19 on this Market:The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
To get the short-term and long-term impact of COVID-19 on this Market.Please visit: https://www.fortunebusinessinsights.com/industry-reports/immunology-market-100657

Regional Analysis:Rising Prevalence of Autoimmune Diseases to Propel Market in North AmericaThe market in North America is predicted to account for the largest share in the global market during the forecast period owing to the growing cases of autoimmune and immunological disorders in the region. The rising acceptance of advanced immunology drugs will further create lucrative business opportunities for the market in the forthcoming years. The market in Asia Pacific is likely to rise tremendously during the forecast period owing to the rising prevalence of immunological diseases.The developing healthcare infrastructure will further enhance growth in the region. The rising popularity of advanced immunology drugs such as immunosuppressants along with existing drug classes of monoclonal antibody (mAb) and polyclonal antibody (pAb) will encourage the healthy growth of the market during the forecast period.
Quick Buy –  Immunology Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100657

Key Development:April 2019: AbbVie Inc. announced that it has extended its immunology portfolio with the launch of a new product offering called SKYRIZI (risankizumab-rzaa). The new drug will be used for the treatment of moderate to severe plaque psoriasis
List of the Key Companies Operating in the Immunology Market are:AbbVie Inc.
Janssen Global Services, LLC (Johnson & Johnson)F. Hoffmann-La Roche LtdAmgen Inc.Pfizer Inc.Novartis AGAstellas
Bristol-Myers Squibb CompanyMerck Sharp & Dohme Corp.UCB SAALLERGANOther Prominent Players
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/immunology-market-100657
IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsPrevalence of Autoimmune and Immunological Disorders by Key CountriesOverview of Regulatory Scenario by Key RegionsKey Industry DevelopmentsOverview of Current Advances in R&D for ImmunologyGlobal Immunology Market Analysis, Insights and Forecast, 2015-2026Key Findings / SummaryMarket Analysis, Insights and Forecast – By Drug ClassMonoclonal Antibody (mAb)Fusion ProteinsImmunosuppressantsPolyclonal Antibody (pAb)OthersMarket Analysis, Insights and Forecast – By Disease IndicationRheumatoid ArthritisPsoriatic ArthritisPlaque PsoriasisAnkylosing SpondylitisInflammatory Bowel DiseaseProphylaxis of Organ RejectionOthersMarket Analysis, Insights and Forecast – By Distribution ChannelHospital PharmaciesRetail PharmaciesOnline PharmaciesOthersMarket Analysis, Insights and Forecast – By RegionNorth AmericaEuropeAsia PacificLatin AmericaMiddle East & AfricaTOC Continued….!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/immunology-market-100657
Have a Look at Related Reports:Immunodiagnostics Market Size, Share and Global Trend By Product Instruments, Reagents & Consumables), By Application (Oncology & Endocrinology, Hepatitis & Retrovirus, Cardiac Markers, Infectious Diseases), By End user (Clinical Laboratories, Hospitals, Physician’s Offices), By End-user(Hospitals, Dental Clinics, Academic & Research Institutes) and Geography Forecast till 2026Intravenous Immunoglobulins Market Size, Share and Global Trend By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), Form (Liquid, Lyophilized), End User (Hospitals, Clinics, Homecare) & Geography Forecast till 2025Immune Thrombocytopenia (ITP) Market Size, Share & Industry Analysis, By Type (Acute Immune Thrombocytopenia, and Chronic Immune thrombocytopenia), By Treatment (Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) and Regional Forecast, 2019-2026About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/immunology-market-9140

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.